The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Trial
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Gout
- Focus Therapeutic Use
- Acronyms FORWARD
- Sponsors Menarini
- 28 Jul 2017 This study has been completed in Netherlands (End Date: 11-09-2015).
- 10 Jun 2017 Biomarkers information updated
- 21 Dec 2016 Planned number of patients changed from 182 to 197.